The randomized phase III, double-blind, clinical trial (E5103) enrolled 4,995 patients with human epidermal growth factor receptor 2-negative (HER2-negative) breast cancer and evaluated the efficacy and the safety of humanized monoclonal antibody bevacizumab targeting vascular endothelial growth factor (VEGF) in adjuvant chemotherapeutic setting (1). The rationale of the study was based on the results from the metastatic setting where the combination of bevacizumab with chemotherapy has shown a significant improvement of progression free survival (2-7) and a pathologic complete response in the neoadjuvant setting (8-12). The E5103 aimed to improve patients’ survival outcomes. Patients were randomized in three arms: placebo with doxorubicine and cyclophosphamide followed by paclitaxel (arm A); same chemotherapeutic combination plus bevacizumab (arm B and C); in particular, patients in arm C continued bevacizumab for almost one years, together with radiation and hormonal therapy. Invasive disease-free survival (IDFS) was the primary end point. The 5-year IDFS rates were 77% (95% CI, 71% to 81%) in arm A, 76% (95% CI, 72% to 80%) in arm B, and 80% (95% CI, 77% to 83%) in arm C. The differences in IDFS between the 3 arms were not statistically significant. The overall survival (OS) at 5 years were 90% (95% CI, 87% to 92%), 86% (95% CI, 83% to 88%) and 90% (95% CI, 88% to 92%) in arms A, B and C, respectively. On the same line of the IDFS differences, the differences in OS were not statistically significant between the three groups (1).

The hypothesis lying behind these negative results obtained from this clinical trial are different in our opinion. First, there was a substantial early discontinuation of bevacizumab: about 24% of patients in arm B and 55% in arm C interrupted the treatment due to the adverse events (AEs). The AEs across arms included myelosuppression and neuropathy. Grade ≥3 hypertension was the most commonly frequent in experimental arms, but others bevacizumab-related AEs were similar reported in all arms. Secondly, the discontinuation of therapy due to the AEs provoked by the administration of adjuvant bevacizumab was also responsible for the interruption in the provision of chemotherapy. The pre-planned additional chemotherapeutic regimens for patients enrolled into arms B and C could have been beneficial in improving their IDFS and OS. Thus, the results could have been much different if bevacizumab did not lead to AEs-caused interruption of all the successive treatment schedules of arms B and C. The 40% of patients in arm C did not proceed to bevacizumab monotherapy mostly due to the withdrawn of the consent or due to the toxicity.

Third, the absence of predictive biomarkers, fourth, it should be considered that there are multiple mechanisms of resistance to anti-VEGF therapy such as the induction of
alternative angiogenic pathways (Fibroblast Growth Factor, Hepatocyte Growth Factor c/Met, Platelet-Derived Growth Factor, Epidermal Growth Factor, Insulin-Like Growth Factor), hypoxia-mediated increases, cancer stem cells that can grow without the need of the mitogenic factors present in serum (13), autophagy and compensatory recruitment of vascular progenitors.

Similar results were previously obtained from the BEATRICE clinical trial, a randomized, open-label, phase III trial with 1,290 Triple Negative Breast Cancer (TNBC) patients testing the chemotherapy either alone or with bevacizumab (5 mg/kg every week for 1 year). The primary endpoint was IDFS (14) which was not met: there was no difference between groups in IDFS (HR 0.87; with a smalls difference in 3-year IDFS and 5-year IDFS rates (14,15). Moreover, after 56 months leading to 293 patients been deceased the measured OS was not statistically different between the two groups (HR 0.93, 95% CI, 0.74–1.17; P=0.52). All the other secondary endpoints were in favor of the bevacizumab arm, but none of them was statistically significant (14).

In adjuvant setting the target of treatment should be eventually the micro-metastases present in the body but they are hard-to-be-treated using anti-angiogenic treatments aiming to target blood vessels. Moreover, the potential bevacizumab-resistance could have been also inferred by cancer stem cells capable of proliferating without the need for blood supply or because of other angiogenic pathways.

In conclusion, using treatments capable of blocking the pathways responsible for resistance to bevacizumab along their combination of bevacizumab and not with the use of bevacizumab alone could be interesting to be pursued in combination also with chemotherapy in the adjuvant setting of HER2-negative breast cancer.

Acknowledgments

Funding: None.

Footnote

Provenance and Peer Review: This article was commissioned and reviewed by the Section Editor San-Gang Wu (Department of Radiation Oncology, Xiamen Cancer Center, The First Affiliated Hospital of Xiamen University, Xiamen, China).

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at http://dx.doi.org/10.21037/tcr.2018.10.17). GR serves as an unpaid editorial board member of Translational Cancer Research from Sep 2018 to Aug 2020. The other authors have no conflicts of interest to declare.

Ethical Statement: The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0/.

References

1. Miller KD, O’Neill A, Gradishar W, et al. Double-Blind Phase III Trial of Adjuvant Chemotherapy With and Without Bevacizumab in Patients With Lymph Node-Positive and High-Risk Lymph Node-Negative Breast Cancer (E5103). J Clin Oncol 2018;36:2621-9.

2. von Minckwitz G, Puglisi F, Cortes J, et al. Bevacizumab plus chemotherapy versus chemotherapy alone as second-line treatment for patients with HER2-negative locally recurrent or metastatic breast cancer after first-line treatment with bevacizumab plus chemotherapy (TANIA): an open-label, randomised. Lancet Oncol 2014;15:1269-78.

3. Brušky AM, Hurvitz S, Perez E, et al. RIBBON-2: A Randomized, Double-Blind, Placebo-Controlled, Phase III Trial Evaluating the Efficacy and Safety of Bevacizumab in Combination With Chemotherapy for Second-Line Treatment of Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer. J Clin Oncol 2011;29:4286-93.

4. Robert NJ, Diéras V, Glaspy J, et al. RIBBON-1: Randomized, Double-Blind, Placebo-Controlled, Phase III Trial of Chemotherapy With or Without Bevacizumab for
First-Line Treatment of Human Epidermal Growth Factor Receptor 2-Negative, Locally Recurrent or Metastatic Breast Cancer. J Clin Oncol 2011;29:1252-60.

5. Miles D, Cameron D, Bondarenko I, et al. 1866 First results from the double-blind placebo (PL)-controlled randomised phase III MERiDiAN trial prospectively evaluating plasma (p)VEGF-A in patients (pts) receiving first-line paclitaxel (PAC) +/- bevacizumab (BV) for HER2-negative metastatic breast. Eur J Cancer 2015;51:S287-S288.

6. Miles DW, Chan A, Dirix LY, et al. Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol 2010;28:3239-47.

7. Miller K, Wang M, Gralow J, et al. Paclitaxel plus Bevacizumab versus Paclitaxel Alone for Metastatic Breast Cancer. N Engl J Med 2007;357:2666-76.

8. Nahleh ZA, Barlow WE, Hayes DF, et al. SWOG S0800 (NCI CDR0000636131): addition of bevacizumab to neoadjuvant nab-paclitaxel with dose-dense doxorubicin and cyclophosphamide improves pathologic complete response (pCR) rates in inflammatory or locally advanced breast cancer. Breast Cancer Res Treat 2016;158:485-95.

9. Sikov WM, Berry DA, Perou CM, et al. Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603 (Alliance). J Clin Oncol 2015;33:13-21.

10. Earl HM, Hiller L, Dunn JA, et al. Efficacy of neoadjuvant bevacizumab added to docetaxel followed by fluorouracil, epirubicin, and cyclophosphamide, for women with HER2-negative early breast cancer (ARTemis): an open-label, randomised, phase 3 trial. Lancet Oncol 2015;16:656-66.

11. von Minckwitz G, Eidtmann H, Rezai M, et al. Neoadjuvant Chemotherapy and Bevacizumab for HER2-Negative Breast Cancer. N Engl J Med 2012;366:299-309.

12. Bear HD, Tang G, Rastogi P, et al. Bevacizumab Added to Neoadjuvant Chemotherapy for Breast Cancer. N Engl J Med 2012;366:310-20.

13. Shao J, Fan W, Ma B, et al. Breast cancer stem cells expressing different stem cell markers exhibit distinct biological characteristics. Mol Med Rep 2016;14:4991-8.

14. Cameron D, Brown J, Dent R, et al. Adjuvant bevacizumab-containing therapy in triple-negative breast cancer (BEATRICE): primary results of a randomised, phase 3 trial. Lancet Oncol 2013;14:933-42.

15. Bell R, Brown J, Parmar M, et al. Final efficacy and updated safety results of the randomized phase III BEATRICE trial evaluating adjuvant bevacizumab-containing therapy in triple-negative early breast cancer. Ann Oncol 2017;28:754-60.

Cite this article as: Roviello G, Generali D, Sobhani N. The combination of bevacizumab with chemotherapy is more beneficial in the metastatic setting rather than in the adjuvant setting for the treatment of HER2-negative breast cancer—a commentary on the E5103 randomized phase III clinical study. Transl Cancer Res 2019;8(Suppl 2):S94-S96. doi: 10.21037/tcr.2018.10.17